Development of Biological Products – Innovative Technologies as Prerequisite and Opportunity
Posted on September 27, 2018
Dr. Alexander Jung1 1 Global Technology Management Biologicals, Boehringer Ingelheim Pharma GmbH & Co KG, Birkendorfer Straße 65, 88397 Biberach an der Riss
Senior Manager Technology & Innovation
Dr. Martin M. Herrmann1
Senior Manager Technology & Innovation
Dr. Jan C. Schöning1,2
Head of Global Technology Management
Boehringer Ingelheim Pharma GmbH & Co KG
2 Corresponding Author
Abstract The biopharmaceutical industry is dependent on high-tech in research, development and production for delivering highly efficient and safe drugs to the patient. This triggers a constant need for innovation in a highly controlled environment. In addition, other factors like digitization and n...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
biological therapies, Boehringer Ingelheim Pharma, Dr. Alexander Jung, mammalian cell culture, microbial fermentation processes, monoclonal antibodies, recombinant proteins
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
